Eli Lilly To Buy Back Cymbalta Rights For $400M

Law360, New York (April 19, 2010, 6:31 PM EDT) -- Eli Lilly & Co. said Monday it would repurchase the rights from Boehringer Ingelheim GmbH to develop and market antidepressant Cymbalta in countries outside of the U.S. and Japan, for an upfront payment of $400 million.

Lilly will also pay Boehringer royalties on sales through 2012, the company said in an announcement.

The companies have marketed Cymbalta outside the U.S. and Japan for several years.

Lilly has exclusive rights to Cymbalta in the U.S. and partners with Shionogi & Co. Ltd. in Japan on developing and...
To view the full article, register now.